All the news Showing 10 of 26 articles from: Finance, funding & health economicsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Can investment in hepatitis C treatment be cost saving? Keith Alcorn / 24 November 2020 Direct-acting antiviral treatment for hepatitis C can be cost saving for some countries within five to ten years, especially if they can negotiate lower drug prices, a study presented online at this ... How much can 'Netflix'-style pricing for hepatitis C drugs save? Keith Alcorn / 03 June 2019 A 'Netflix'-style pricing agreement that allows the Australian government to treat an unlimited number of people with hepatitis C for AU$1 billion may result in savings close to US$5 billion, according to ... $51 billion price tag for eliminating hepatitis C by 2030 Keith Alcorn / 11 April 2019 To achieve hepatitis C elimination worldwide by 2030, governments, donors and the private sector will need to spend $51 billion but eliminating hepatitis C will lead to a $19 billion ... Generic DAAs achieve excellent cure rates in Egypt matching those of branded drugs at a fraction of the cost Michael Carter / 01 February 2019 Generic direct-acting antivirals (DAAs) are just as effective and safe as their branded equivalents for the treatment of chronic hepatitis C virus (HCV) infection, according to Egyptian research published in Liver International. Generics achieved ... Early treatment for hepatitis C would be highly cost-effective for Scotland Keith Alcorn / 16 April 2018 Early treatment for hepatitis C is highly cost-effective in Scotland when compared to treatment initiated at the stages of advanced fibrosis or cirrhosis, according to a cost-effectiveness analysis presented on ... Model shows hepatitis C treatment is cost-effective in Japan Liz Highleyman / 27 November 2017 Treatment of chronic hepatitis C with direct-acting antivirals (DAAs) can lead to substantial savings by preventing the development of liver failure and liver cancer, according to a mathematical modelling study presented at the ... High prices of DAAs mean there's been little progress towards achieving WHO target of eliminating HCV by 2030 Michael Carter / 13 September 2017 Only a handful of countries are on course to achieve the World Health Organization (WHO) target of eliminating hepatitis C virus (HCV) as a major public health concern by 2030, ... Countries and donors should aim for new $90-$90-$90 target on HIV, hepatitis, TB drug prices, study shows Keith Alcorn / 27 July 2017 HIV, hepatitis B and C and tuberculosis (TB) can each be treated for less than $90 a year where generic drugs can be made available, Dzintars Gotham of Imperial College, London, reported ... US Veterans Affairs and Australia show potential for rapid elimination of hepatitis C Keith Alcorn / 15 November 2016 If sufficient money is available to pay for direct-acting antivirals (DAAs), the US Veterans Affairs (VA) could cure the majority of veterans under its care of hepatitis C within three years, and ... Australia shows an alternative to rationing hepatitis C treatment Keith Alcorn / 06 June 2016 The Hepatitis C Trust has announced it is considering seeking judicial review of NHS England's decision to impose a cap on the number of people treated for hepatitis C in ... ← First123Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Access to medicines & diagnostics Hepatitis C elimination Models of care Finance, funding & health economics National policy European policy International policy Activism and civil society Pharmaceutical industry Social issues Conference news Email bulletin archive